For the third quarter, Royalty Pharma delivered 9% growth in top-line portfolio receipts and 8% growth in adjusted EBITDA. The firm modestly raised guidance, but disappointing results from Novartis' phase 3 pelacarsen trial prompted Royalty Pharma to record a $150 million impairment charge.
Royalty Pharma’s portfolio includes market-leading therapies for a wide range of diseases, enabling stable future royalty streams and high returns on investments over the next decade.
Underperformance of key portfolio products due to major regulatory changes could put pressure on Royalty Pharma’s cash flows.
Metric | RPRX | VRTX | PFE |
|---|---|---|---|
Price/Earnings (Normalized) | 48.31 | 29.66 | 13.29 |
Price/Book Value | 4.52 | 6.53 | 1.85 |
Price/Sales | 12.60 | 10.63 | 2.60 |
Price/Cash Flow | 10.93 | 29.59 | 11.20 |
Metric | RPRX | VRTX | PFE |
|---|---|---|---|
Quick Ratio | 1.29 | 1.72 | 1.00 |
Current Ratio | 1.29 | 2.34 | 1.42 |
Interest Coverage | 4.09 | 94.80 | 2.39 |
Metric | RPRX | VRTX | PFE |
|---|---|---|---|
Return on Assets (Normalized) | −3.17% | 17.70% | 8.49% |
Return on Equity (Normalized) | −9.28% | 25.16% | 19.73% |
Return on Invested Capital (Normalized) | −1.46% | 20.26% | 12.71% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@?@M<#d | LOCK|?^&zl | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$F#&SR | LOCK|H??s | $99B | |||
| Moderna Inc MRNA | LOCK|#BLjJp | LOCK|!# | $90B | |||
| argenx SE ADR ARGX | LOCK|>d!h!k | LOCK|c! | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#lvPVQ! | LOCK|&Ww | $48B | |||
| Incyte Corp INCY | LOCK|BG%$NDY | LOCK|g% | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<cl$&B | LOCK|G!qG | $22B | |||
| BioNTech SE ADR BNTX | LOCK|klZ&Xh | LOCK|F%N | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&bWKG?v | LOCK|?$ | $16B |
United States